<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121430</url>
  </required_header>
  <id_info>
    <org_study_id>2052108140</org_study_id>
    <nct_id>NCT03121430</nct_id>
  </id_info>
  <brief_title>Study of Drug Eluting Peripheral Vascular Stent System in Superficial Femoral Artery Stenosis and /or Occlusion</brief_title>
  <official_title>The Safety and Efficacy of Drug Eluting Peripheral Vascular Stent System for the Treatment of Superficial Femoral Artery Stenosis and /or Occlusion: a Multi-center Stratified Randomized Single- Blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Zylox Medical Device Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Osmunda Medical Device Technology, Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Zylox Medical Device Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of drug eluting peripheral vascular stent system for the treatment of superficial
      femoral artery stenosis and / or occlusion, there is better in effectiveness and clinical
      performance compared with similar products already on the market.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized study designed to enroll 138 patients with
      superficial femoral artery stenosis and /or occlusion who will be randomized 1:1 to be
      treated with the Drug eluting peripheral vascular stent system versus the commercially
      available Nitinol Stent System (Cordis Corporation). Patients will receive Color Doppler
      Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging at 6th month and 12th month post
      procedure. Clinical visits are scheduled at 0~30 days, 6 months, 12 months, and telephone
      visits are scheduled at 1 month, 3months, and 9 months. Furthermore, CDU will also be
      performed at baseline in all participants of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary patency rate at 12 months after operation</measure>
    <time_frame>12 months</time_frame>
    <description>the rate of the target lesion diameter stenosis &lt;50% patients confirmed by Color Doppler Ultrasonography (CDU) imaging at 12 months postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>primary patency rate at 6 months after operation</measure>
    <time_frame>6 months</time_frame>
    <description>the rate of the target lesion diameter stenosis &lt;50% patients confirmed by Color Doppler Ultrasonography (CDU) imaging at 6 months postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization rate</measure>
    <time_frame>Preoperative，up to 1 month，6 months，12 months</time_frame>
    <description>subject found that the presence of restenosis in the target lesion in follow-up , and need to re-intervention or bypass graft according to the clinical symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent fracture rate</measure>
    <time_frame>6 months、12 months</time_frame>
    <description>using the Dual Fluoroscopic Imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Superficial Femoral Artery Stenosis</condition>
  <condition>Superficial Femoral Artery Occlusion</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects using the drug eluting peripheral vascular stent system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects using the Nitinol Stent System (Cordis Corporation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug eluting peripheral vascular stent system</intervention_name>
    <description>Drug eluting peripheral vascular stent system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nitinol Stent System</intervention_name>
    <description>Nitinol Stent System、Color Doppler Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Cordis Corporation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria in Preoperative:

          -  Aged from 18 to 85 years old, male or female

          -  Subject's target lesions were stenosis and/or occlusion

          -  Subject is aware of the study content, showing sufficient compliance with the research
             protocol and sign the Informed Consent

        Exclusion Criteria in Preoperative:

          -  In-Stent Restenosis(IRS) or restenosis after drug-eluting balloon administration

          -  Serum creatinine concentration of the subject is higher than 1.5 times of the upper
             limit of normal serum creatinine concentration

          -  Subject with coagulation abnormalities should not be performed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Zhong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guo Wei</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gao Feng</last_name>
    <phone>+86 (0)10 8220-7036</phone>
    <phone_ext>823</phone_ext>
    <email>md@osmundacn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Jie</last_name>
    <phone>13819565660</phone>
    <email>jie.liang@zyloxmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 9, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral arterial disease</keyword>
  <keyword>Drug eluting peripheral vascular stent system</keyword>
  <keyword>primary patency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

